Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Indian Heart Journal, published by Elsevier, is a distinguished peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. Founded in 1961, this journal has been a pivotal resource for researchers, healthcare professionals, and students, providing a platform for innovative studies and insights into heart health. The journal transitioned to an Open Access model in 2013, ensuring widespread dissemination of vital research findings to enhance global understanding of cardiovascular diseases. Ranked in the Q3 category for Cardiology and Cardiovascular Medicine in 2023, it holds a reputable position in the medical community, with a Scopus rank of #222 out of 387 journals in the same field, placing it in the 42nd percentile. The Indian Heart Journal strives to foster advances in clinical practice and research while addressing the unique cardiac health challenges faced in India and beyond.

International Journal of Cardiology Cardiovascular Risk and Prevention is a distinguished Open Access journal published by ELSEVIER, dedicated to advancing research in the realms of cardiology and cardiovascular medicine. With an ISSN of 2772-4875 and based in the Netherlands, this journal has rapidly established itself as a critical resource for academics and practitioners since its inception in 2021. The journal currently holds a respectable impact factor and occupies the Q2 quartile in both Cardiology and Cardiovascular Medicine and Internal Medicine categories, reflecting its commitment to sharing high-quality research. Researchers can take advantage of its open-access model, ensuring that cutting-edge findings are freely available to a global audience. The journal not only covers innovative studies on cardiovascular risk factors and prevention strategies but also aims to facilitate interdisciplinary collaboration. With an ongoing trajectory from 2021 to 2024, the International Journal of Cardiology Cardiovascular Risk and Prevention is poised to remain a pivotal platform for dialogue and discovery in the evolving landscape of cardiovascular health.

JAMA Cardiology, published by the American Medical Association, is a leading peer-reviewed journal in the field of cardiology and cardiovascular medicine, with an impressive impact factor signifying its influence and relevance within the medical community. Established in 2016, this journal has quickly gained recognition, currently positioned in the Q1 quartile and ranked #2 out of 387 in its field according to Scopus, reflecting its commitment to high-quality research dissemination. As an esteemed publication, JAMA Cardiology aims to advance the understanding of cardiovascular health through rigorous studies, reviews, and clinical insights. The journal is dedicated to serving a diverse audience of researchers, clinicians, and students, ensuring they have access to groundbreaking findings and comprehensive discussions that shape contemporary cardiology. Although it is not an open-access journal, articles published within it play a pivotal role in informing clinical practice and guiding future research in cardiovascular health, making it an essential resource for anyone engaged in this vital field.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

The Scandinavian Cardiovascular Journal, published by Taylor & Francis Ltd, is a distinguished peer-reviewed journal aimed at advancing the field of cardiology and cardiovascular medicine. With an impressive history dating back to 1967 and a forward-looking perspective until 2024, it has consistently contributed valuable research and insights, making it essential reading for anyone involved in cardiovascular healthcare. The journal holds a strong position in the academic community, reflected in its Q2 rating in both Cardiology and Cardiovascular Medicine, and a similar classification in the broader field of Medicine as of 2023. It is indexed in multiple databases, with a Scopus rank of #178 out of 387 in its category, placing it in the 54th percentile. The journal provides open access options, promoting wider dissemination of knowledge while supporting both researchers and practitioners dedicated to improving cardiovascular health. Its focus on high-quality, impactful research makes it an invaluable resource for professionals and students alike, keen to stay at the forefront of cardiology advancements.

The Journal of the American Heart Association, published by WILEY, serves as a premier platform for advancing cardiovascular medicine through its commitment to open access, fostering global dissemination of cutting-edge research since 2012. It proudly holds a prestigious position within the top quartile (Q1) in the categories of Cardiology and Cardiovascular Medicine, as evidenced by its Scopus ranking of #49 out of 387 journals, placing it in the 87th percentile. With a focus on innovative studies and transformative findings, this journal is essential for cardiologists, researchers, and healthcare professionals seeking to stay at the forefront of cardiovascular knowledge. The journal aims to bridge the gap between basic science and clinical practice, presenting findings that shape the future of heart health treatment and prevention. As a resource for academic and clinical communities alike, the Journal of the American Heart Association is dedicated to enhancing the understanding and treatment of cardiovascular diseases globally.

The European Journal of Preventive Cardiology, published by Oxford University Press, is a leading international journal dedicated to the field of cardiology and cardiovascular medicine. With an impact factor that underscores its prestige—ranking in the top quartile (Q1) of both cardiology and epidemiology categories—the journal serves as a critical resource for researchers and practitioners seeking to advance their understanding of preventive strategies in cardiovascular health. Since its inception in 1999, it has provided a platform for high-quality research and reviews that address the epidemiology of cardiovascular diseases, risk factor management, and innovative prevention methodologies. Notably, it currently ranks #21 out of 387 in Medicine - Cardiology and #13 out of 148 in Medicine - Epidemiology according to Scopus, highlighting its influential position in these essential biomedical fields. The journal also provides open access options, allowing both readers and authors the opportunity to engage with groundbreaking research and enhance the dissemination of knowledge. With a commitment to excellence, the European Journal of Preventive Cardiology is an invaluable asset for those dedicated to the prevention of cardiovascular diseases.

Cardiovascular Diagnosis and Therapy, an esteemed journal in the field of Cardiology and Cardiovascular Medicine, is published by AME PUBLISHING COMPANY, based in Hong Kong, China. With an ISSN of 2223-3652 and an E-ISSN of 2223-3660, this open-access journal aims to present cutting-edge research that significantly advances diagnostic and therapeutic practices in cardiovascular health. Recognized for its impact, it holds a 2023 category quartile ranking of Q2 and is positioned at rank #124 out of 387 in Scopus, reflecting its noteworthy contribution to medical literature with a percentile of 68th. The journal welcomes contributions that span various aspects of cardiovascular research, including clinical trials, epidemiological studies, and innovative therapeutic approaches, making it a vital resource for researchers, practitioners, and students alike, committed to improving cardiovascular care.

Cardiology Journal, published by VIA MEDICA, stands as a prominent resource in the field of cardiology and cardiovascular medicine, with an ISSN of 1897-5593 and an E-ISSN of 1898-018X. Recognized for its Open Access model established since 1994, this journal facilitates widespread dissemination of critical research findings, allowing practitioners and researchers globally to access valuable insights without barriers. Based in Poland, with an address at UL SWIETOKRZYSKA 73, 80-180 GDANSK, it has achieved a respectable Q2 classification in 2023 for both Cardiology and Miscellaneous Medicine categories, reflecting its influence and quality within the scholarly community. With a Scopus ranking placing it at #117 out of 387 in Cardiology, it lies within the 69th percentile, underpinning its commitment to advancing knowledge in cardiovascular health. The journal’s converged years extending from 2006 to 2024 ensure it captures ongoing developments in a rapidly evolving field. As such, the Cardiology Journal serves as an indispensable platform for researchers, professionals, and students dedicated to exploring the frontiers of cardiac science and improving patient care.